Lunai Bioworks (LNAI) Income from Continuing Operations (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Income from Continuing Operations of 1585312.0 for Q1 2026, up 63.57% year-over-year from 969219.11 in Q1 2025, and up 18.49% quarter-over-quarter from 1944922.0 in Q4 2025.
Lunai Bioworks (LNAI) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Lunai Bioworks' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 1585312.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 63.57% year-over-year to 1585312.0; the TTM figure through Mar 2026 stood at 133366534.0 (down 69.19% YoY), while the FY2025 annual figure was 272646865.0, down 7.92% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1585312.0, up from 1944922.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1585312.0 in Q1 2026, with the low at 126405540.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 6201465.0 (2022), against an average of 24339056.53.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 1095.16% in 2024, then surged 93.58% in 2025.
- Lunai Bioworks' Income from Continuing Operations stood at 4457748.0 in 2022, then dropped by 1.96% to 4545059.0 in 2023, then retreated by 2.2% to 4645207.0 in 2024, then soared by 58.13% to 1944922.0 in 2025, then gained by 18.49% to 1585312.0 in 2026.
- Business Quant data shows LNAI's Income from Continuing Operations at 1585312.0 in Q1 2026, 1944922.0 in Q4 2025, and 3430760.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | -1.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.59 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Sep 30, 2025 | -3.43 Mn |
| Jun 30, 2025 | -126.41 Mn |
| Mar 31, 2025 | -4.35 Mn |
| Dec 31, 2024 | -4.65 Mn |
| Sep 30, 2024 | -53.46 Mn |
| Jun 30, 2024 | -16.37 Mn |
| Mar 31, 2024 | -51.73 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -9.18 Mn |
| Jun 30, 2023 | -23.20 Mn |
| Mar 31, 2023 | -4.33 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -7.70 Mn |
| Jun 30, 2022 | -90.24 Mn |
| Mar 31, 2022 | -6.20 Mn |
| Dec 31, 2021 | -6.58 Mn |
| Sep 30, 2021 | -10.41 Mn |
| Jun 30, 2021 | -17.36 Mn |